318 related articles for article (PubMed ID: 26626320)
21. Outcomes of rotigotine clinical trials: effects on motor and nonmotor symptoms of Parkinson's disease.
Lyons KE; Pahwa R
Neurol Clin; 2013 Aug; 31(3 Suppl):S51-9. PubMed ID: 23931954
[TBL] [Abstract][Full Text] [Related]
22. A randomized study of rotigotine dose response on 'off' time in advanced Parkinson's disease.
Nicholas AP; Borgohain R; Chaná P; Surmann E; Thompson EL; Bauer L; Whitesides J; Elmer LW;
J Parkinsons Dis; 2014; 4(3):361-73. PubMed ID: 24643203
[TBL] [Abstract][Full Text] [Related]
23. Long-term safety and tolerability of rotigotine transdermal system in patients with early-stage idiopathic Parkinson's disease: a prospective, open-label extension study.
Elmer LW; Surmann E; Boroojerdi B; Jankovic J
Parkinsonism Relat Disord; 2012 Jun; 18(5):488-93. PubMed ID: 22326237
[TBL] [Abstract][Full Text] [Related]
24. A controlled trial of rotigotine monotherapy in early Parkinson's disease.
Parkinson Study Group
Arch Neurol; 2003 Dec; 60(12):1721-8. PubMed ID: 14676046
[TBL] [Abstract][Full Text] [Related]
25. Effect of rotigotine on sleep and quality of life in Parkinson's disease patients: post hoc analysis of RECOVER patients who were symptomatic at baseline.
Ghys L; Surmann E; Whitesides J; Boroojerdi B
Expert Opin Pharmacother; 2011 Sep; 12(13):1985-98. PubMed ID: 21790503
[TBL] [Abstract][Full Text] [Related]
26. Reduction of gastrointestinal symptoms in Parkinson's disease after a switch from oral therapy to rotigotine transdermal patch: a non-interventional prospective multicenter trial.
Woitalla D; Kassubek J; Timmermann L; Lauterbach T; Berkels R; Grieger F; Müller T
Parkinsonism Relat Disord; 2015 Mar; 21(3):199-204. PubMed ID: 25595315
[TBL] [Abstract][Full Text] [Related]
27. The development of the rotigotine transdermal patch: a historical perspective.
Waters C
Neurol Clin; 2013 Aug; 31(3 Suppl):S37-50. PubMed ID: 23931953
[TBL] [Abstract][Full Text] [Related]
28. Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease.
Jankovic J; Watts RL; Martin W; Boroojerdi B
Arch Neurol; 2007 May; 64(5):676-82. PubMed ID: 17502466
[TBL] [Abstract][Full Text] [Related]
29. Impact of 6-month earlier versus postponed initiation of rotigotine on long-term outcome: post hoc analysis of patients with early Parkinson's disease with mild symptom severity.
Timmermann L; Asgharnejad M; Boroojerdi B; Dohin E; Woltering F; Elmer LW
Expert Opin Pharmacother; 2015; 16(10):1423-33. PubMed ID: 25997442
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of rotigotine transdermal system in severe restless legs syndrome: a randomized, double-blind, placebo-controlled, six-week dose-finding trial in Europe.
Oertel WH; Benes H; Garcia-Borreguero D; Geisler P; Högl B; Saletu B; Trenkwalder C; Sommerville KW; Schollmayer E; Kohnen R; Stiasny-Kolster K;
Sleep Med; 2008 Mar; 9(3):228-39. PubMed ID: 17553743
[TBL] [Abstract][Full Text] [Related]
31. Overnight switch from oral dopaminergic agonists to transdermal rotigotine patch in subjects with Parkinson disease.
LeWitt PA; Boroojerdi B; MacMahon D; Patton J; Jankovic J
Clin Neuropharmacol; 2007; 30(5):256-65. PubMed ID: 17909303
[TBL] [Abstract][Full Text] [Related]
32. The Efficacy Profile of Rotigotine During the Waking Hours in Patients With Advanced Parkinson's Disease: A Post Hoc Analysis.
LeWitt PA; Poewe W; Elmer LW; Asgharnejad M; Boroojerdi B; Grieger F; Bauer L
Clin Neuropharmacol; 2016; 39(2):88-93. PubMed ID: 26882318
[TBL] [Abstract][Full Text] [Related]
33. Transdermal Patch of Rotigotine Attenuates Freezing of Gait in Patients with Parkinson's Disease: An Open-Label Comparative Study of Three Non-Ergot Dopamine Receptor Agonists.
Ikeda K; Hirayama T; Takazawa T; Kawabe K; Iwasaki Y
Intern Med; 2016; 55(19):2765-2769. PubMed ID: 27725534
[TBL] [Abstract][Full Text] [Related]
34. Rotigotine transdermal patch for the treatment of Parkinson's disease and restless legs syndrome.
Boroojerdi B; Wolff HM; Braun M; Scheller DK
Drugs Today (Barc); 2010 Jul; 46(7):483-505. PubMed ID: 20683503
[TBL] [Abstract][Full Text] [Related]
35. Rotigotine transdermal patch in the management of Parkinson's disease (PD) and its night-time use for PD-related sleep disorders.
Antonini A; Bernardi L; Calandrella D; Mancini F; Plebani M
Funct Neurol; 2010; 25(1):21-5. PubMed ID: 20626993
[TBL] [Abstract][Full Text] [Related]
36. Rotigotine transdermal patch for the treatment of Parkinson's Disease.
Perez-Lloret S; Rey MV; Ratti PL; Rascol O
Fundam Clin Pharmacol; 2013 Feb; 27(1):81-95. PubMed ID: 22320451
[TBL] [Abstract][Full Text] [Related]
37. The effects of transdermal rotigotine on non-motor symptoms of Parkinson's disease: a multicentre, observational, retrospective, post-marketing study.
Valldeoriola F; Salvador A; Gómez-Arguelles JM; Marey J; Moya M; Ayuga Á; Ramírez F
Int J Neurosci; 2018 Apr; 128(4):369-375. PubMed ID: 29249180
[TBL] [Abstract][Full Text] [Related]
38. Patients' perception of Parkinson's disease-associated pain following initiation of rotigotine: a multicenter non-interventional study.
Timmermann L; Oehlwein C; Ransmayr G; Fröhlich H; Will E; Schroeder H; Lauterbach T; Bauer L; Kassubek J
Postgrad Med; 2017 Jan; 129(1):46-54. PubMed ID: 27883297
[TBL] [Abstract][Full Text] [Related]
39. Rotigotine transdermal patch: a review of its use in the treatment of Parkinson's disease.
Sanford M; Scott LJ
CNS Drugs; 2011 Aug; 25(8):699-719. PubMed ID: 21790211
[TBL] [Abstract][Full Text] [Related]
40. Switching from an oral dopamine receptor agonist to rotigotine transdermal patch: a review of clinical data with a focus on patient perspective.
Chung SJ; Asgharnejad M; Bauer L; Benitez A; Boroojerdi B; Heidbrede T; Little A; Kim HJ
Expert Rev Neurother; 2017 Jul; 17(7):737-749. PubMed ID: 28548894
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
